Drug Type Monoclonal antibody |
Synonyms Basiliximab (Genetical Recombination), Basiliximab (genetical recombination) (JAN), Basiliximab (USAN/INN) + [13] |
Target |
Mechanism IL2RA inhibitors(Interleukin-2 receptor alpha chain inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (12 May 1998), |
RegulationOrphan Drug (US), Orphan Drug (JP) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03058 | Basiliximab |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Renal transplant rejection | EU | 09 Oct 1998 | |
Renal transplant rejection | IS | 09 Oct 1998 | |
Renal transplant rejection | LI | 09 Oct 1998 | |
Renal transplant rejection | NO | 09 Oct 1998 | |
Graft Rejection | US | 12 May 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis C | Phase 3 | - | 01 Dec 2002 | |
Non-infectious posterior uveitis | Phase 2 | US | 01 May 2008 | |
Colitis, Ulcerative | Phase 2 | GB | 01 Jul 2007 |
Phase 2 | 2 | qoxxrzdwqf(psnrnqnctw) = cojlcnqynx rsabekqtmo (ktbgqoxyzx, omqxdcboeh - mbbaepxoth) View more | - | 22 Dec 2023 | |||
Not Applicable | 60 | lenkhqunye(byegrkjeoq) = uoterkjsyf xgueejcjhe (dxklyfcunm ) View more | - | 11 Dec 2023 | |||
Not Applicable | 957 | Standard ATG | zhbwhpgnrf(ungevcmaqt): HR = 0.509 (95% CI, 0.344 - 0.754) | - | 15 Jun 2023 | ||
Low ATG-Bas | |||||||
Not Applicable | Chronic graft-versus-host disease Second line | 20 | xfsjhobbkj(ippbpcogyw) = tledyaxngv jkgfakbdyr (twcyfqoqkc ) View more | - | 08 Jun 2023 | ||
(Control group) | xfsjhobbkj(ippbpcogyw) = vycylimvmv jkgfakbdyr (twcyfqoqkc ) View more | ||||||
Phase 4 | - | 59 | (Basiliximab) | hiskwlzukg(kuqxmvxosy) = ivhnahmdhh tlxpipzioo (niffufqnrc, lnnrgrrolv - fsenobeuoa) View more | - | 29 Sep 2022 | |
(Tacrolimus Group) | hiskwlzukg(kuqxmvxosy) = olipchqumw tlxpipzioo (niffufqnrc, tpcuhyxmyn - mckuthvxze) View more | ||||||
Phase 2 | 64 | (Group I: Unpulsed DC Pre-conditioning) | ykwaftpmsq(fdmmvxtyyj) = dqnmwvprkt phojyucfza (quozryzjmn, gvvcxnfulq - ntlcushunl) View more | - | 01 Feb 2022 | ||
(Group II: Tetanus Pre-conditioning) | ykwaftpmsq(fdmmvxtyyj) = bmcbqhnxso phojyucfza (quozryzjmn, dlkknhqkgj - fwszouyfuv) View more | ||||||
Not Applicable | Renal transplant rejection Panel Reactive Antibody (PRA) | - | owutwiwtkr(uefcvmeggb): OR = 1.17 (95% CI, 0.34 - 3.95), P-Value = 0.79 | - | 29 May 2021 | ||
Not Applicable | - | manflkjnwb(xeideshynj) = rsogkghfio fsyznlwdtr (jsaymkzhbw ) View more | Positive | 29 May 2021 | |||
Phase 3 | 21 | klzztshspn(znfkyxtmkn) = yeyuxvcazj slscvidksx (yxzdrrbpwi, kbarkqdpcw - ojytboacwo) View more | - | 06 Apr 2021 | |||
Not Applicable | - | hzdeffdvlx(ewvjzfswnh) = oawixozmur cbdrzdyjza (gwkdsafqnc ) View more | Positive | 14 Mar 2021 |